Pentatricopeptide repeat-containing protein 1, mitochondrial (PTCD1)

Pentatricopeptide repeat-containing protein 1, mitochondrial (PTCD1), is an RNA-binding protein localized in the mitochondrial matrix, composed of eight PPR domains and an N-terminal mitochondrial targeting sequence[1][3][5]. PTCD1 binds mitochondrial leucine tRNAs and precursor RNAs, acting as a negative regulator that limits the abundance of leucine tRNAs and attenuates mitochondrial protein translation[1]. Knockdown of PTCD1 increases levels of mitochondrial-encoded proteins (Complex I and IV subunits) and enhances oxidative phosphorylation activity[1]. Loss of PTCD1 impairs mitochondrial ribosome assembly, forces cells to rely on glycolysis for energy, and is associated with mitochondrial fragmentation and cristae abnormalities[2]. Reduced PTCD1 expression and coding variants have been linked to poor prognosis in bladder urothelial carcinoma and increased risk of Alzheimer's disease, suggesting a role in cancer progression, immune regulation, and neurodegeneration[2][3]. PTCD1 is not established as a direct therapeutic target, and no approved drugs interact with it.

Other names

PTCD1KIAA0632Pentatricopeptide repeat domain protein 1Pentatricopeptide repeat-containing protein 1, mitochondrial

Not applicable; no known drugs act directly on PTCD1. Indirect mechanisms involve modulation of mitochondrial translation and oxidative phosphorylation.